Pharma giants announce diabetes drug partnership

04/29/2013 | PharmaLive.com

Merck and Pfizer announced plans to combine Merck's DPP-4 inhibitor Januvia with Pfizer's SGLT-2 inhibitor ertugliflozin to treat type 2 diabetes. Merck paid Pfizer $60 million and will split costs and revenue 60-40 with Pfizer. "This is like the Yankees and Red Sox combining their scouting departments," former Pfizer research chief John LaMattina wrote on Twitter, but Diabetic Investor publisher David Kliff said the resulting drug will be just "another tool in the toolbox."

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC